There isn’t a single “tocilizumab patent expiration.” Patent expiry depends on jurisdiction and on which patent family you’re talking about (composition of matter, formulation, methods of use, manufacturing, etc.). Here’s the gist:
- Core composition patents: Most of the basic composition-of-matter patents for tocilizumab have expired in major markets (US/EU) by the mid-to-late 2010s. However, there can be other patents tied to manufacturing processes, specific formulations, or variants that extend protection in some places.
- Regulatory data/exclusivity (US): In the United States, biologics are protected by 12 years of data exclusivity from the first FDA approval of the product under the Biologics Price Competition and Innovation Act (BPCIA). Tocilizumab (Actemra) was first approved in 2010, so this data exclusivity runs until around 2022, after which biosimilar competition could begin if the sponsor meets all regulatory requirements. Pediatric exclusivity can add extra months.
- Market exclusivity and SPCs (EU): In Europe, even after a core patent expires, market protection can be extended by supplementary protection certificates (SPCs) for up to about 5 additional years (often plus a pediatric extension of up to 6 months). This means some EU protection can run into the early to mid-2020s depending on the country and the specific patent family.
- Other patents: There are also patents on uses (e.g., specific diseases or indications), combinations, dosing methods, and manufacturing technologies that may still be in force in some jurisdictions even after the core composition patent expires.
If you want precise dates for a specific region and for a specific patent family (e.g., US composition patent, EU SPC, or a use/method patent), tell me the jurisdiction and which aspect you’re interested in (composition, use, formulation, manufacturing). I can then pull the current public patent status and give you a clearer expiration window.
Note: This is general information. For legal or business decisions, consult a patent attorney or freedom-to-operate expert who can review the exact patent families in the relevant markets.